The clinical-stage biopharmaceutical company, which focuses on therapies affecting the central nervous system, has seen its shares rise by 52% over the past year but fall 11% so far in 2023. The healthcare company on Tuesday released the third positive trial result regarding KarXT, a therapy to treat adults with schizophrenia. The latest trial, KarXT's Phase 3 EMERGENT-3 trial, met its primary endpoint, the company said, showing an 8.4-point reduction on the Positive and Negative Syndrome Scale total score compared to a placebo.